Novel multiple sclerosis agents-associated cardiotoxicity: A real-world pharmacovigilance study

Background:Emerging novel therapeutics have been developed to hamper the progression of multiple sclerosis (MS). However, the adverse events related to these new agents remain largely unknown. Therefore, we sought to investigate the cardiovascular complications of these drugs.Methods: Utilizing data from the U.S. food and drug administration (FDA) adverse events reporting system (FAERS), we comprehensively evaluated the cardiovascular complications of the newly FDA-approved anti-MS modifying therapies approved since 2015.

Source: International Journal of Cardiology - May 25, 2022 Category: Cardiology Authors: Zaki Al-Yafeai, Alexander Carvajal-Gonz ález, Hamzah Abduljabar, Muhammed Arvas, Shaan Patel, Neev Patel Source Type: research